Background and Purpose: Candida albicans (C. albicans) is an opportunistic fungus that can colonize women's mucosal epithelial cell surfaces, causing vulvovaginitis in specific circumstances. The major genes contributing to drug resistance in C. albicans are the candida drug resistance (CDR) and multi drug resistance (MDR) genes. The purpose of this study was to evaluate the CDR-2 and MDR-1 gene expression patterns in C. albicans strains isolated from patients with recurrent vulvovaginal candidiasis. Materials and Methods: In this study, 40 isolates of fluconazole-resistant C. albicans were cultured on Sabouraud dextrose agar. These isolates were collected from women with vulvovaginitis who were referred to a clinic in Tehran, Iran, and transferred to a mycology laboratory. Then, RNA was extracted from the isolates using phenolchloroform and glass beads, and the complementary DNA (cDNA) was synthetized. To det ect the semi-quantitative expression of CDR-2 and MDR-1 genes, the reverse transcriptase-PCR (RT-PCR) technique was performed using specific primers. Results: Our findings indicated that of the 40 C. albicans isolates, 35 (87.5%) strains were positive for mRNA of the CDR-2 gene, 32 (80%) strains expressed mRNA of the MDR-1 gene, and 30 (75%) strains were confirmed to express mRNA of both the CDR-2 and MDR-1 genes simultaneously using the RT-PCR assay. Conclusion: According to the obtained results, the expression rates of CDR-2 and MDR-1 genes were high in fluconazole-resistant C. albicans isolates, which can cause treatments to fail and result in chronic infections. Inhibiting these important genes using novel or natural agents can help with the treatment of chronic and recurrent vaginitis.
Introduction
omen of reproductive age, consumers of contraceptive steroidal drugs or any of the widespread anti-bacterial agents, diabetic or pregnant women, and patients with an immunological deficiency have the predisposing factors for vulvovaginal candidiasis (VVC) [1] . The rising prevalence of fluconazoleresistant C. albicans strains is a major problem after long-term treatment of recurrent VVC (RVVC). Fluconazole resistance can occur through different mechanisms involving mutations in the drug target enzyme and sterol 14a-demethylase (14DM), alterations in sterol biosynthesis, increased expression of the ERG11 gene, as well as overexpression of genes coding membrane transport proteins of the ABC transporter (CDR-1/CDR-2) or the major facilitator (MDR1) superfamilies [2, 3] .
In addition, drug resistance can emerge by environmental factors, leading to fungal colonization or substituting a resistant species such as Candida glabrata or Candida krusei with a sensitive one [4] [5] [6] .
Previous studies illustrated that developing efflux pumps is the most frequent mechanism for azole resistance in Candida species. Efflux pumps coded by two carrier gene families include CDR-1 and CDR-2 genes belonging to the ATP-binding cassette superfamily, as well as MDR-1 genes from the major facilitator superfamily [7, 8] . It was confirmed that enhancing the expression levels of CDR-1, CDR-2, and MDR-1 in C. albicans causes fluconazole resistance [9, 10] 
Materials and Methods

C. albicans strains and culture conditions
Fourteen fluconazole-resistant C. albicans isolates were obtained from patients with VVC, who were admitted to gynecology centers in Tehran, Iran. The isolates were identified using the conventional method based on colony color on CHROM agar Candida, and molecular methods included polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) [16] . The isolates were stored in sterilized distilled water until the time of the experiment.
Moreover, resistance to fluconazole was shown by disk diffusion assay performed according to the Clinical Laboratory Standards Institute recommenddations in our previous study [16] . The standard strain of C. albicans (ATCC10231) was used as a fluconazole sensitive species. This study was carried out in Medical Mycology and Parasitology laboratory in Iran University of Medical Sciences, 2016.
Total RNA extraction in Candida isolates
For this study, isolates were cultured on Sabouraud dextrose agar medium (SDA, Merck, Germany) and incubated at 37 o C for 24 h. The cell wall of C. albicans was disrupted using an RNA lysis buffer and glass beads. Then, RNA was extracted using RNx-plus (Cinnagen, Tehran, Iran) and a chloroform/isoamyl alcohol solution [17] . After centrifugation, the sediment was dissolved in distilled water and stored at -20 o C until use.
Elimination of genomic DNA from the total RNA
To eliminate DNA contamination from the RNA, all the samples were treated by deoxyribonuclease (DNase) enzyme (Fermentas, Paisley, England) according to the following steps: 1 µg of RNA was added to a sterilized, nuclease-free microtube; 1 µl of DNase 10X reaction buffer and 1 µl of DNase-1 were added to microtubes; 2 µl of ethylenediaminetetraacetic acid (25 mM) was added to each microtube, and the microtubes were stored at 65 o C for 10 min. The purified RNA was used for complementary DNA (cDNA) synthesis.
cDNA synthesis and reverse transcriptase-PCR (RT-PCR) assay
After DNase enzyme treatment, RNA was converted to cDNA according to the manufacturer's recommendations using a cDNA synthesis kit (Fermentas, USA). RT-PCR was performed with the reactions containing 2 μl of template cDNA, 0.6 μl of each specific primer for the MDR-1 and CDR-2 genes, 10 μl of Taq DNA polymerase, MgCl2, dNTP, and vivantis buffer), as well as 6.8 μl of diethylpyrocarbonate (DEPC) water in a final volume of 20 μl. The RT-PCR protocol was begun with an initial denaturation at 94°C for 5 min, followed by 35 cycles of denaturation (94°C for 1 min), annealing (58°C for 1 min), and extension (72°C for 1 min); the protocol was terminated with a final extension step at 72°C for 3 min. The appropriate negative and positive controls were included in each test.
The primers for MDR-1 and CDR-2 were designed by Gene Runner software, and their sequence is presented in Table 1 . ACT1 was used as the house-keeping gene and for confirmation of the PCR process in all the molecular tests. Ultimately, the PCR products were visualized by gel electrophoresis. 
Results
Fluconazole susceptibility testing against C. albicans isolates
All the 40 C. albicans isolates were resistant to 25 μg of fluconazole in disk diffusion method. The inhibition zone was determined < 14 mm against fluconazole.
Patients' age ranged between 18 and 50 years, and 57% of the patients consumed several antibiotics, 28% cases used contraceptives, and 15% of the women had diabetes.
RNA extraction
The quality of RNA was evaluated by gel electrophoresis. Figure 1 illustrates the total RNA of the isolates before and after the DNase enzyme treatment. The quantity of RNA was determined using BioPhotometer plus (Eppendorf AG, Germany), and the RNA concentration for all the samples was adjusted to 1.5 ng. 
MDR-1 and CDR-2 gene expression
An RT-PCR reaction was carried out using special primers for MDR-1 and CDR-2 for 40 C. albicans specimens. The semi-quantitative expression of both MDR-1 and CDR-2 was assessed in C. albicans clinical isolates (figures 2, 3) using RT-PCR. The PCR product sizes were 125 bp and 148 bp for CDR-2 and MDR-1, respectively, as explained previously [18] . 
Discussion
Recent headways in our understanding of the molecular mechanisms causing azole resistance in C. albicans revealed that increased efflux of drug, mediated mostly by the ATP-binding cassette (ABC) and the major facilitator superfamily (MFS) transporters, leads to resistance to azole anti-fungal agents [19, 20] .
Our findings indicated that the expression rates of MDR and CDR genes were high in fluconazoleresistant C. albicans. In our study, the high expression rates of genes in the isolates may be due to taking high doses of fluconazole, as the patients had RVVC. The expression level of CDR-2 was higher than that of MDR-1 in the isolates, indicating that the role of CDR in forming fluconazole resistance in C. albicans is more pronounced than that of MDR-1. Regarding the assumption that CDR is specific to C. albicans, these results were favorable for our isolates.
Emerging fluconazole resistant C. albicans isolates leads to a wide range of complications in RVVC treatment, the most important of which is biofilm formation, that is, aggregate of a rigid network by Candida. The expression of MDR and CDR genes during the early phase of biofilm formation and alterations in membrane sterol composition are responsible for resistance of these biofilms against azole agents.
Although resistance is multifactorial and other molecular mechanisms participate in this phenolmenon, it is worth mentioning that the expression of drug efflux pumps during the early phase of biofilm formation and alterations in membrane sterol composition contribute to resistance of these biofilms against azoles [21, 22] . Consistent with our results, Gulat et al. assessed the expression levels of CDR-1, CDR-2, and MDR-1 in fluconazole-resistant Candida albicans isolates using real-time PCR. Our findings indicated that the expression levels of CDR-1, CDR-2, and MDR-1 genes in sensitive isolates were lower compared to resistant ones, suggesting that high expression levels of efflux genes is a major mechanism for fluconazole resistance in Candida albicans [23] .
Zhang et al. evaluated the expression levels of CDR-1, CDR-2, MDR-1, and FLU-1 in 18 fluconazole-resistant isolates of Candida strains from VVC patients and reported a significant increase in CDR-1 expression, while expression levels of CDR-2, MDR-1, and FLU-1 did not significantly elevate [24] .
In our study, lack of expression of MDR-1 and CDR-2 genes in 7.5% of the cases may be explained by the report presented by Lohberger et al. indicating the expression levels of drug-resistance genes (i.e., CDR-1, CDR-2, MDR-1, and ERG-11) are controlled by transcription factors such as TAC-1, which are responsible for controlling the expression of CDR-1 and CDR-2. MRR-1 and UPC-2 factors are responsible for controlling the expression levels of MDR-1 and ERG-11, respectively. Moreover, there are some enhancing mutations (GOF) in activated alleles for increasing the expression levels of the target genes [19] . It can be concluded that the lack of MDR-1 and CDR-2 in some isolates in our study may be associated with the activation of ultra-genetic factors rather than transcription factors including ERG11 [25, 26] , which can be considered in future studies.
In [28] .
Our findings were in line with those of Salari et al. who evaluated the CDR-1, CDR-2, MDR-1, and ERG11 genes expression in C. albicans clinically isolated from HIV-infected patients in Iran by realtime PCR. Their results indicated that the CDR-1 gene expression in fluconazole-resistant C. albicans increased significantly compared to other known genes [29] .
This finding was not in congruence with the results of the current study. This discrepancy could be related to the source of infection, the number of isolates, and genetic diversity of isolates in different geographic areas.
Conclusion
The high expression levels of MDR-1 and CDR-2 genes in C. albicans isolates in RVVC highlights the important role of these genes in developing fluconazole resistance, causing treatment attempts to fail and leading to chronic infections. Therefore, inhibition of the key genes involved in the disease as well as combination therapy using novel synthetic or natural drugs could help patients with chronic and recurrent VVC.
